What is dementia? Alzheimer's Association. https://www.alz.org/alzheimers-dementia/what-is-dementia. Accessed Feb. 8, 2021.
The dementias: Hope through research. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Dementia-Hope-Through-Research. Accessed Feb. 8, 2021.
Larson EB. Evaluation of cognitive impairment of dementia. https://www.uptodate.com/contents/search. Accessed Feb. 8, 2021.
AskMayoExpert. Dementia (adult). Mayo Clinic; 2020.
Press D, et al. Treatment of dementia. https://www.uptodate.com/contents/search. Accessed Feb. 8, 2021.
Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020; doi:10.1016/S0140-6736(20)30367-6.
Brown A. Allscripts EPSi. Mayo Clinic. Feb. 10, 2021.
Creuzfeldt-Jakob disease, classic (CJD): Occurrence and transmission. Centers for Disease Control and Prevention. https://www.cdc.gov/prions/cjd/occurrence-transmission.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fprions%2Fcjd%2Foccurance-transmisison.html. Accessed Feb. 11, 2021.
Graff-Radford NR (expert opinion). Mayo Clinic. Feb. 11, 2021.
Dementia. Merck Manual Professional Version. https://www.merckmanuals.com/professional/neurologic-disorders/delirium-and-dementia/dementia. Accessed Feb. 11, 2021.
Press D, et al. Prevention of dementia. https://www.uptodate.com/contents/search. Accessed Feb. 11, 2021.
Assessing risk for Alzheimer's disease. National Institute on Aging. https://www.nia.nih.gov/health/assessing-risk-alzheimers-disease. Accessed Feb. 8, 2021.
Medications for memory. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory. Accessed Feb. 11, 2021.
Tips for communicating with a person with dementia. Alzheimer's Association. https://www.alzheimers.org.uk/about-dementia/symptoms-and-diagnosis/symptoms/tips-for-communicating-dementia. Accessed Feb. 11, 2021.
Coupland CA, et al. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Internal Medicine. 2019; doi:10.1001/jamainternmed.2019.0677.
Abdi Beshir S , et al. Aducanumab therapy to treat Alzheimer's disease: A narrative review. International Journal of Alzheimer's Disease. 2022; doi:10.1155/2022/9343514.
Aducanumab approved for treatment of Alzheimer's disease. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/treatments/aducanumab. Accessed Sept. 28, 2022.
Graff-Radford J (expert opinion). Mayo Clinic. Sept. 30, 2022.
Shi M, et al. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: A focus on aducanumab and lecanemab. Frontiers in Aging and Neuroscience. 2022; doi:10.3389/fnagi.2022.870517.
Cummings J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimer's and Dementia. 2022; doi:10.1002/trc2.12295.